Orchestra BioMed Holdings Files 8-K on Security Holder Vote

TL;DR

Orchestra BioMed Holdings is having a shareholder vote on June 20, 2024.

AI Summary

Orchestra BioMed Holdings, Inc. filed an 8-K on June 20, 2024, to report on the submission of matters to a vote of security holders. The company, formerly known as Health Sciences Acquisitions Corp 2, is incorporated in Delaware and has its principal executive offices in New Hope, Pennsylvania.

Why It Matters

This filing indicates that Orchestra BioMed Holdings is seeking approval from its security holders for important corporate actions, which could impact the company's future direction and shareholder rights.

Risk Assessment

Risk Level: low — The filing is a routine disclosure of a shareholder vote, not an event that inherently introduces new financial or operational risks.

Key Players & Entities

• Orchestra BioMed Holdings, Inc. (company) — Registrant
• Health Sciences Acquisitions Corp 2 (company) — Former company name
• June 20, 2024 (date) — Date of report
• Delaware (jurisdiction) — State of incorporation
• New Hope, Pennsylvania (location) — Principal executive offices

FAQ

Key Financial Figures

• $0.0001 — h registered Common stock, par value $0.0001 per share OBIO The Nasdaq Global Mark

Filing Documents

• tm2417692d1_8k.htm (8-K) — 27KB
• 0001104659-24-073435.txt ( ) — 197KB
• obio-20240620.xsd (EX-101.SCH) — 3KB
• obio-20240620_lab.xml (EX-101.LAB) — 33KB
• obio-20240620_pre.xml (EX-101.PRE) — 22KB
• tm2417692d1_8k_htm.xml (XML) — 4KB

07. Submission of Matters to a Vote of Security Holders

Item 5.07. Submission of Matters to a Vote of Security Holders. On June 20, 2024, Orchestra BioMed Holdings, Inc. (the "Company") held its 2024 Annual Meeting of Stockholders (the "Annual Meeting"). A total of 35,786,497 shares of the Company's common stock, par value $0.0001 per share ("Common Stock"), were entitled to vote as of April 26, 2024, the record date for the Annual Meeting. There were 28,647,942 shares of Common Stock represented at the Annual Meeting, at which the Company's stockholders were asked to vote on two proposals, each of which is described in more detail in the Company's definitive proxy statement for the Annual Meeting filed with the Securities and Exchange Commission on April 30, 2024. Set forth below are the matters acted upon by the Company's stockholders, and the final voting results of each such proposal. Proposal No. 1: Election of Directors Votes regarding the election of the two Class I director nominees were as follows: Director Name Votes For Votes Withheld Broker Non-Votes Eric A. Rose, M.D. 22,471,631 2,170,666 4,005,645 Jason Aryeh 24,004,640 637,657 4,005,645 Based on the votes set forth above, the Company's stockholders elected each of the two nominees set forth above to serve as a Class I director of the Company until the 2027 annual meeting of stockholders and until such director's respective successor is duly elected and qualified. Proposal No. 2: Ratification of Appointment of Independent Registered Public Accounting Firm The proposal to ratify the appointment of Ernst & Young LLP as the Company's independent registered public accounting firm for the Company's fiscal year ending December 31, 2024 (the "Auditor Ratification Proposal"), received the following votes: Votes For Votes Against Abstentions Broker Non-Votes 28,620,141 25,400 2,401 – Based on the votes set forth above, the Auditor Ratification Proposal was approved. 2

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. ORCHESTRA BIOMED HOLDINGS, INC. By: /s/ Andrew Taylor Name: Andrew Taylor Title: Chief Financial Officer Date: June 20, 2024 3

View Full Filing

View this 8-K filing on SEC EDGAR